SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) **06-1397316** (I.R.S. employer Identification umber)

251 Ballardvale Street Wilmington, Massachusetts 01887 (978) 658-6000

(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

Joanne Acford General Counsel

General Counsel Charles River Laboratories International, Inc. 251 Ballardvale Street Wilmington, Massachusetts 01887 (978) 658-6000 (Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Richard D. Truesdell, Jr. Davis Polk & Wardwell 450 Lexington Avenue New York, New York 10017 (212) 450-4000

Approximate date of commencement of proposed sale to the public: from time to time after the effective date.

If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. o

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. 333-92383

If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. o

EXPLANATORY NOTE

We initially issued the warrants in a transaction exempt from the registration requirements of the Securities Act of 1933. Each warrant entitles the holder to purchase 7.60 shares of our common stock at an exercise price of \$5.19 per share, subject to adjustment in some circumstances. We filed a registration

statement (Registration No. 333-92383) in order to permit the holders of these warrants and shares of our common stock acquired on exercise of these warrants to resell those securities in transactions that are registered under the Securities Act of 1933.

This Post-Effective Amendment No. 3 to Registration Statement on Form S-1 on Form S-3 (File No. 333-92383) is filed solely to add the following additional selling security holders to the table appearing on pages 52 through 55 of the Registration Statement:

	Number of Warrants and Underlying Common Stock Owned Prior to Resale of Warrants				Ownership After Resale of Warrants
Name and Address of Holders	Number of Warrants	Number of Shares Underlying the Warrants	Percentage of Common Stock Owned Prior to Resale	Number of Warrants Offered by Holder	Percentage of Shares of Common Stock
Basso Holdings Ltd. (f/k/a AIG SoundShore Holdings Ltd.) 1266 East Main Street Stamford, CT 06902	12,000	91,200	_	12,000	_
DKR SoundShore Strategic Holding Fund Ltd. (f/k/a AIG SoundShore Strategic Holding Fund Ltd.) 1281 East Main Street Stamford, CT 06902	3,000	22,800	_	3,000	_

None of the above holders has a material relationship with us, except as described in the Registration Statement, as amended.

The contents of the Registration Statement on Form S-1 on Form S-3 (File No. 333-92383) are incorporated by reference herein.

2

PART II INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 16. EXHIBITS

	Exhibit <u>No.</u>	Description	
	23.1*	Consent of PricewaterhouseCoopers LLP.	
*	Filed her	rewith.	
		3	

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Post-Effective Amendment No. 3 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wilmington, State of Massachusetts, on the 12th day of September, 2005.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

By: /s/ Thomas F. Ackerman

Thomas F. Ackerman Corporate Senior Vice President and Chief Financial Officer

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 3 to the Registration Statement has been signed by the following persons in the capacities indicated on September 12, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1933, this Post-Effective Amendment No. 3 to the Registration Statement has been signed by the following persons in the capacities indicated as of September 12, 2005.

Signatures

By: /s/ James C. Foster James C. Foster Title

President, Chief Executive Officer and Chairman

By:	/s/ Thomas A. Ackerman Thomas F. Ackerman		Corporate Senior Vice President and Chief Financial Officer					
By:	/s/ Stephen D. Chubb Stephen D. Chubb		Director					
By:	/s/ George E. Massaro George E. Massaro		Director					
By:	/s/ Linda McGoldrick Linda McGoldrick		Director					
By:	/s/ George M. Milne, Jr. George M. Milne, Jr.		Director					
		4						
By:	/s/ Douglas E. Rogers Douglas E. Rogers	Director						
By:	/s/ Samuel O. Thier Samuel O. Thier	Director						
By:	/s/ William H. Waltrip William H. Waltrip	Director						
		5						
EXHIBIT INDEX								
Exhibit No.		Description						
23.1*	23.1* Consent of PricewaterhouseCoopers LLP.							
* Filed herewith.								
6								

CONSENT OF REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated March 9, 2005 relating to the financial statements and financial statement schedule, management's assessment of the effectiveness of internal control over financial reporting and the effectiveness of internal control over financial reporting which appears in Charles River Laboratories International Inc.'s Annual Report on Form 10-K for the year ended December 25, 2004. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

PricewaterhouseCoopers LLP

Boston, Massachusetts September 9, 2005